BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 12453646)

  • 1. Oligodendroglioma: pathology and molecular biology.
    Engelhard HH; Stelea A; Cochran EJ
    Surg Neurol; 2002 Aug; 58(2):111-7; discussion 117. PubMed ID: 12453646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
    Cairncross JG; Ueki K; Zlatescu MC; Lisle DK; Finkelstein DM; Hammond RR; Silver JS; Stark PC; Macdonald DR; Ino Y; Ramsay DA; Louis DN
    J Natl Cancer Inst; 1998 Oct; 90(19):1473-9. PubMed ID: 9776413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic differences between neurocytoma and dysembryoplastic neuroepithelial tumor and oligodendroglial tumors.
    Fujisawa H; Marukawa K; Hasegawa M; Tohma Y; Hayashi Y; Uchiyama N; Tachibana O; Yamashita J
    J Neurosurg; 2002 Dec; 97(6):1350-5. PubMed ID: 12507133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
    Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
    Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Correlation between loss of heterozygosity on chromosome 1p and 19q and expression of MGMT, p53 and Ki-67 proteins in gliomas].
    Huang L; Jiang T; Yuan F; Li GL; Xu LX; Cui Y
    Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):752-8. PubMed ID: 22335907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nogo-a expression in glial CNS tumors: a tool to differentiate between oligodendrogliomas and other gliomas?
    Kuhlmann T; Gutenberg A; Schulten HJ; Paulus W; Rohde V; Bruck W
    Am J Surg Pathol; 2008 Oct; 32(10):1444-53. PubMed ID: 18685489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allelic losses in oligodendroglial and oligodendroglioma-like neoplasms: analysis using microsatellite repeats and polymerase chain reaction.
    Johnson MD; Vnencak-Jones CL; Toms SA; Moots PM; Weil R
    Arch Pathol Lab Med; 2003 Dec; 127(12):1573-9. PubMed ID: 14632576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma.
    Gupta M; Djalilvand A; Brat DJ
    Am J Clin Pathol; 2005 Nov; 124(5):755-68. PubMed ID: 16203285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas.
    Fallon KB; Palmer CA; Roth KA; Nabors LB; Wang W; Carpenter M; Banerjee R; Forsyth P; Rich K; Perry A
    J Neuropathol Exp Neurol; 2004 Apr; 63(4):314-22. PubMed ID: 15099021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.
    Reifenberger J; Reifenberger G; Liu L; James CD; Wechsler W; Collins VP
    Am J Pathol; 1994 Nov; 145(5):1175-90. PubMed ID: 7977648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Localization of the neuronal class III beta-tubulin in oligodendrogliomas: comparison with Ki-67 proliferative index and 1p/19q status.
    Katsetos CD; Del Valle L; Geddes JF; Aldape K; Boyd JC; Legido A; Khalili K; Perentes E; Mörk SJ
    J Neuropathol Exp Neurol; 2002 Apr; 61(4):307-20. PubMed ID: 11939586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression.
    Hoang-Xuan K; He J; Huguet S; Mokhtari K; Marie Y; Kujas M; Leuraud P; Capelle L; Delattre JY; Poirier J; Broët P; Sanson M
    Neurology; 2001 Oct; 57(7):1278-81. PubMed ID: 11591848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular genetic evidence for subtypes of oligoastrocytomas.
    Maintz D; Fiedler K; Koopmann J; Rollbrocker B; Nechev S; Lenartz D; Stangl AP; Louis DN; Schramm J; Wiestler OD; von Deimling A
    J Neuropathol Exp Neurol; 1997 Oct; 56(10):1098-104. PubMed ID: 9329453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization.
    Bigner SH; Matthews MR; Rasheed BK; Wiltshire RN; Friedman HS; Friedman AH; Stenzel TT; Dawes DM; McLendon RE; Bigner DD
    Am J Pathol; 1999 Aug; 155(2):375-86. PubMed ID: 10433931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.
    Li YX; Shi Z; Aibaidula A; Chen H; Tang Q; Li KK; Chung NY; Chan DT; Poon WS; Mao Y; Wu J; Zhou L; Chan AK; Ng HK
    Oncotarget; 2016 Oct; 7(40):64615-64630. PubMed ID: 27556304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas.
    Bauman GS; Ino Y; Ueki K; Zlatescu MC; Fisher BJ; Macdonald DR; Stitt L; Louis DN; Cairncross JG
    Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):825-30. PubMed ID: 11020580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of cell proliferation, epidermal growth factor receptor, and bcl-2 immunoexpression as prognostic factors for patients with World Health Organization grade 2 oligodendroglioma.
    Reis-Filho JS; Faoro LN; Carrilho C; Bleggi-Torres LF; Schmitt FC
    Cancer; 2000 Feb; 88(4):862-9. PubMed ID: 10679656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma].
    Xiong J; Liu Y; Li C; Zhu JJ; Ye ZR; Mao Y; Wang Y
    Zhonghua Bing Li Xue Za Zhi; 2009 Jul; 38(7):445-50. PubMed ID: 19781190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nogo-A: a useful marker for the diagnosis of oligodendroglioma and for identifying 1p19q codeletion.
    Marucci G; Di Oto E; Farnedi A; Panzacchi R; Ligorio C; Foschini MP
    Hum Pathol; 2012 Mar; 43(3):374-80. PubMed ID: 21835431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.